Milestone Pharmaceuticals (MIST) announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer, CCO. Sandoval will serve as a member of Milestone’s executive leadership team and will provide business-focused legal counsel across all functional areas.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule
- Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
- Milestone Pharmaceuticals announces U.S. availability of cardamyst
- Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing
- Milestone Pharmaceuticals: Undervalued CARDAMYST Opportunity with EU Upside and Strong Risk‑Reward Supporting Buy Rating